Masters Speciality Pharma enters agreement with ApoPharma
4 September 2014 | By Masters
Masters Speciality Pharma signs agreement for the exclusive distribution of Ferriprox® (deferiprone)...
List view / Grid view
News
GeNeuro successful Phase 2a clinical study reinforces novel approach to treat multiple sclerosis
3 September 2014 | By GeNeuro
GeNeuro SA, a pioneer of new therapies for neurology disorders, announced positive results from a one-year, open-label extension of a Phase IIa study...
New cell model to speed up development of brain tumour drugs
3 September 2014 | By The University of Nottingham
New research from The University of Nottingham looks set to improve screening for new cancer drugs and drug delivery systems specifically designed for children with brain tumours...
Selvita licenses Cresset’s computational tools for SAR analysis and ligand-based design
3 September 2014 | By kdm communications
Cresset is pleased to announce that Selvita S.A., a drug discovery company located in Krakow, Poland, has licensed Cresset’s Forge and Spark...
Subgroup Analysis of ENGAGE AF-TIMI 48 explores the relationship between edoxaban dose, concentration, anti-factor Xa activity and outcomes
3 September 2014 | By Daiichi Sankyo
Daiichi Sankyo Company, Limited announced data from a subgroup analysis of the phase 3 ENGAGE AF-TIMI 48 study, that explores the relationship between edoxaban dose, concentration and anti-factor Xa activity in patients with non-valvular atrial fibrillation...
Data published in The Lancet show that IDegLira (insulin degludec/liraglutide; Xultophy®) improves glycaemic control in type 2 diabetes with no weight gain and a lower rate of hypoglycaemia compared to insulin degludec
3 September 2014 | By Novo Nordisk
The Lancet Diabetes & Endocrinology has published the phase 3a DUAL™ I study investigating IDegLira (insulin degludec/liraglutide; Xultophy®) − once-daily, single injection insulin degludec (Tresiba®▼ ) and liraglutide (Victoza®)...
ESC Congress 2014 Hot Line Session: Favourable effect of Pradaxa® on kidney function over time compared to warfarin
3 September 2014 | By Boehringer Ingelheim
New data presented indicate that kidney function decline is less pronounced in patients with an irregular heartbeat who are treated with Pradaxa® (dabigatran etexilate) compared to warfarin...
European Medicines Agency welcomes new Head of Communication Department and new Head of Human Resources
3 September 2014 | By European Medicines Agency
The European Medicines Agency is pleased to announce two new appointments to its management team...
Teva announces UK High Court gives positive judgment in the company’s patent case against AstraZeneca
3 September 2014 | By Teva
Court decision invalidating AZ's patent supports Teva’s launch of DuoResp Spiromax® in UK...
Gilenya® data at ACTRIMS-ECTRIMS to show Novartis is redefining MS treatment goals for patients
3 September 2014 | By Novartis
Novartis announced that new analyses to be presented at the Joint ACTRIMS-ECTRIMS Meeting in Boston, USA from September 10-13, 2014...
Merck to present new data in five tumor types from studies svaluating pembrolizumab, the company’s investigational anti-PD-1 antibody, at ESMO 2014
3 September 2014 | By Merck
Merck announced the presentation of data from ongoing clinical trials evaluating the anti-tumor activity of pembrolizumab, the company’s investigational anti-PD-1 antibody...
Amgen submits Marketing Authorization Application for talimogene laherparepvec to the European Medicines Agency
3 September 2014 | By Amgen
First Marketing Authorization Application for an oncolytic immunotherapy in the European Union...
CleveXel Pharma partners with Guilin Pharmaceutical to develop two new anti-malarial products
3 September 2014 | By Andrew Lloyd & Associates
CleveXel Pharma announces that the company has entered into a new partnering agreement with Guilin Pharmaceutical, a Chinese company located in Shanghai, regarding the development of two new products...
Sanofi and Regeneron present detailed positive results from four pivotal Alirocumab trials at ESC Congress 2014
2 September 2014 | By Sanofi
Sanofi and Regeneron Pharmaceuticals, Inc. announced detailed positive results from four Phase 3 ODYSSEY trials of alirocumab in people with hypercholesterolemia...
Daiichi Sankyo further expands TaNeDS collaborative Drug Discovery Program in Europe
2 September 2014 | By Daiichi Sankyo
Daiichi Sankyo Company, Limited announced details of the application for its Take a New Challenge for Drug Discovery Global Programme 2014, a collaborative drug discovery initiative for universities and research institutes in Europe...
